menu
    • menu
    [{"orgOrder":0,"company":"Selecta Biosciences","sponsor":"Swedish Orphan Biovitrum AB","pharmaFlowCategory":"D","therapeuticArea":"Musculoskeletal","country":"","productType":"Large molecule","year":"2020","type":"Licensing Agreement","leadProduct":"Pegadricase","moa":"","graph1":"Musculoskeletal","graph2":"Phase II","graph3":"Selecta Biosciences","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Musculoskeletal","amount2New":0.10000000000000001,"dosageForm":"Intravenous Infusion","sponsorNew":"Selecta Biosciences \/ Sobi","highestDevelopmentStatusID":"8","companyTruncated":"Selecta Biosciences \/ Sobi"},{"orgOrder":0,"company":"Selecta Biosciences","sponsor":"Swedish Orphan Biovitrum AB","pharmaFlowCategory":"D","therapeuticArea":"Musculoskeletal","country":"","productType":"Large molecule","year":"2020","type":"Licensing Agreement","leadProduct":"Pegadricase","moa":"","graph1":"Musculoskeletal","graph2":"Phase II","graph3":"Selecta Biosciences","amount2":0.10000000000000001,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Musculoskeletal","amount2New":0.10000000000000001,"dosageForm":"Intravenous Infusion","sponsorNew":"Selecta Biosciences \/ Sobi","highestDevelopmentStatusID":"8","companyTruncated":"Selecta Biosciences \/ Sobi"},{"orgOrder":0,"company":"Swedish Orphan Biovitrum AB","sponsor":"Selecta Biosciences","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"","productType":"Large molecule","year":"2020","type":"Not Applicable","leadProduct":"Pegadricase","moa":"","graph1":"Musculoskeletal","graph2":"Phase III","graph3":"Swedish Orphan Biovitrum AB","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Swedish Orphan Biovitrum AB \/ Selecta Biosciences","highestDevelopmentStatusID":"10","companyTruncated":"Swedish Orphan Biovitrum AB \/ Selecta Biosciences"},{"orgOrder":0,"company":"Selecta Biosciences","sponsor":"Swedish Orphan Biovitrum AB","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"","productType":"Large molecule","year":"2020","type":"Not Applicable","leadProduct":"Pegadricase","moa":"","graph1":"Rheumatology","graph2":"Phase III","graph3":"Selecta Biosciences","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Rheumatology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Selecta Biosciences \/ Sobi","highestDevelopmentStatusID":"10","companyTruncated":"Selecta Biosciences \/ Sobi"},{"orgOrder":0,"company":"IGAN Biosciences","sponsor":"Selecta Biosciences","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"","productType":"Large molecule","year":"2020","type":"Licensing Agreement","leadProduct":"Pegadricase","moa":"","graph1":"Immunology","graph2":"Preclinical","graph3":"IGAN Biosciences","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"IGAN Biosciences \/ Selecta Biosciences","highestDevelopmentStatusID":"4","companyTruncated":"IGAN Biosciences \/ Selecta Biosciences"},{"orgOrder":0,"company":"3S Bio Inc","sponsor":"Selecta Biosciences","pharmaFlowCategory":"D","therapeuticArea":"Musculoskeletal","country":"","productType":"Large molecule","year":"2020","type":"Licensing Agreement","leadProduct":"Pegadricase","moa":"","graph1":"Musculoskeletal","graph2":"Phase III","graph3":"3S Bio Inc","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"3S Bio Inc \/ Selecta Biosciences","highestDevelopmentStatusID":"10","companyTruncated":"3S Bio Inc \/ Selecta Biosciences"},{"orgOrder":0,"company":"Selecta Biosciences","sponsor":"Swedish Orphan Biovitrum AB","pharmaFlowCategory":"D","therapeuticArea":"Rheumatology","country":"","productType":"Large molecule","year":"2023","type":"Licensing Agreement","leadProduct":"Pegadricase","moa":"","graph1":"Rheumatology","graph2":"Phase III","graph3":"Selecta Biosciences","amount2":0.70999999999999996,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Rheumatology","amount2New":0.70999999999999996,"dosageForm":"Infusion","sponsorNew":"Selecta Biosciences \/ Swedish Orphan Biovitrum AB","highestDevelopmentStatusID":"10","companyTruncated":"Selecta Biosciences \/ Swedish Orphan Biovitrum AB"}]

    Find Clinical Drug Pipeline Developments & Deals for Pegadricase

    Menu

    Pegadricase

    DEVELOPMENTS

    DIGITAL CONTENT

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Selecta Biosciences

                            U.S.A arrow
                            2024 ACI Convention
                            Not Confirmed

                            Selecta Biosciences

                            U.S.A arrow
                            2024 ACI Convention
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Pegadricase,ImmTOR

                            Therapeutic Area : Rheumatology

                            Study Phase : Phase III

                            Sponsor : Swedish Orphan Biovitrum AB

                            Deal Size : $705.0 million

                            Deal Type : Licensing Agreement

                            DEALS_DEV arrow-down

                            Selecta Announces Transition of Manufacturing and Clinical Operations of ImmTOR for SEL-212 to Commercializati...

                            Details : Sobi will transition the manufacturing and development rights of ImmTOR for SEL-212 to Sobi. SEL-212, a combination of Selecta’s ImmTOR immune tolerance platform and a therapeutic uricase enzyme (pegadricase), is in development for chronic refractory g...

                            Brand Name : SEL-212

                            Molecule Type : Large molecule

                            Upfront Cash : $75.0 million

                            October 31, 2023

                            Lead Product(s) : Pegadricase,ImmTOR

                            Therapeutic Area : Rheumatology

                            Highest Development Status : Phase III

                            Sponsor : Swedish Orphan Biovitrum AB

                            Deal Size : $705.0 million

                            Deal Type : Licensing Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            3S Bio Inc

                            China arrow
                            2024 ACI Convention
                            Not Confirmed

                            3S Bio Inc

                            China arrow
                            2024 ACI Convention
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Pegadricase

                            Therapeutic Area : Musculoskeletal

                            Study Phase : Phase III

                            Sponsor : Selecta Biosciences

                            Deal Size : $4.0 million

                            Deal Type : Licensing Agreement

                            DEALS_DEV arrow-down

                            3SBio Inc. Received Milestone Payment of USD 4 Million Upon Commencement of Phase III Clinical Program of SEL-...

                            Details : Selecta Biosciences, 3SBio partner, has commenced the phase III clinical program of a combination therapy involving SEL-212 for the treatment of chronic refractory gout on behalf of SobiTM, and has made a milestone payment of USD 4 million to 3SBio.

                            Brand Name : SEL-212

                            Molecule Type : Large molecule

                            Upfront Cash : Undisclosed

                            November 23, 2020

                            Lead Product(s) : Pegadricase

                            Therapeutic Area : Musculoskeletal

                            Highest Development Status : Phase III

                            Sponsor : Selecta Biosciences

                            Deal Size : $4.0 million

                            Deal Type : Licensing Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            IGAN Biosciences

                            U.S.A arrow
                            2024 ACI Convention
                            Not Confirmed

                            IGAN Biosciences

                            U.S.A arrow
                            2024 ACI Convention
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Pegadricase,IgA proteases

                            Therapeutic Area : Immunology

                            Study Phase : Preclinical

                            Sponsor : Selecta Biosciences

                            Deal Size : Undisclosed

                            Deal Type : Licensing Agreement

                            DEALS_DEV arrow-down

                            Selecta Biosciences and IGAN Biosciences Collaborate to Study ImmTOR™ Immune Tolerance Platform in Combinati...

                            Details : The companies have entered into a Research License and Option agreement to study Selecta’s ImmTOR™ immune tolerance platform in combination with IGAN’s immunoglobulin A (IgA) protease for the treatment of IgA Nephropathy (IgAN).

                            Brand Name : SEL-212

                            Molecule Type : Large molecule

                            Upfront Cash : Undisclosed

                            October 08, 2020

                            Lead Product(s) : Pegadricase,IgA proteases

                            Therapeutic Area : Immunology

                            Highest Development Status : Preclinical

                            Sponsor : Selecta Biosciences

                            Deal Size : Undisclosed

                            Deal Type : Licensing Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            Selecta Biosciences

                            U.S.A arrow
                            2024 ACI Convention
                            Not Confirmed

                            Selecta Biosciences

                            U.S.A arrow
                            2024 ACI Convention
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Pegadricase

                            Therapeutic Area : Musculoskeletal

                            Study Phase : Phase III

                            Sponsor : Swedish Orphan Biovitrum AB

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Sobi and Selecta Biosciences Announce Topline Data of SEL-212 From the Phase 2 COMPARE Study

                            Details : Patients with tophi showed a substantially higher overall response rate for SEL-212 versus pegloticase and a statistically significant overall reduction in mean SUA levels for SEL-212 versus pegloticase.

                            Brand Name : SEL-212

                            Molecule Type : Large molecule

                            Upfront Cash : Not Applicable

                            September 30, 2020

                            Lead Product(s) : Pegadricase

                            Therapeutic Area : Musculoskeletal

                            Highest Development Status : Phase III

                            Sponsor : Swedish Orphan Biovitrum AB

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            Swedish Orphan Biovitrum AB

                            Sweden arrow
                            2024 ACI Convention
                            Not Confirmed

                            Swedish Orphan Biovitrum AB

                            Sweden arrow
                            2024 ACI Convention
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Pegadricase

                            Therapeutic Area : Musculoskeletal

                            Study Phase : Phase III

                            Sponsor : Selecta Biosciences

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            First Patient Randomized in Sobi's Phase 3 DISSOLVE Clinical Program of SEL-212 for Chronic Refractory Gout

                            Details : The phase 3 DISSOLVE clinical programme a randomized double-blind, placebo-controlled study in which SEL-212 will be evaluated at two doses of ImmTOR, and one dose of pegadricase in both studies.

                            Brand Name : SEL-212

                            Molecule Type : Large molecule

                            Upfront Cash : Not Applicable

                            September 23, 2020

                            Lead Product(s) : Pegadricase

                            Therapeutic Area : Musculoskeletal

                            Highest Development Status : Phase III

                            Sponsor : Selecta Biosciences

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            06

                            Selecta Biosciences

                            U.S.A arrow
                            2024 ACI Convention
                            Not Confirmed

                            Selecta Biosciences

                            U.S.A arrow
                            2024 ACI Convention
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Pegadricase

                            Therapeutic Area : Musculoskeletal

                            Study Phase : Phase II

                            Sponsor : Swedish Orphan Biovitrum AB

                            Deal Size : $100.0 million

                            Deal Type : Licensing Agreement

                            DEALS_DEV arrow-down

                            Sobi And Selecta Announce Closing of Previously Announced Strategic Licensing Agreement For Sel-212

                            Details : The licensing agreement includes the global rights, excluding China, for the product SEL-212. SEL-212 is a combination of Selecta's tolerogenic ImmTOR immune tolerance platform and a therapeutic uricase enzyme that is designed for the treatment of chroni...

                            Brand Name : Undisclosed

                            Molecule Type : Large molecule

                            Upfront Cash : $100.0 million

                            July 28, 2020

                            Lead Product(s) : Pegadricase

                            Therapeutic Area : Musculoskeletal

                            Highest Development Status : Phase II

                            Sponsor : Swedish Orphan Biovitrum AB

                            Deal Size : $100.0 million

                            Deal Type : Licensing Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            07

                            Selecta Biosciences

                            U.S.A arrow
                            2024 ACI Convention
                            Not Confirmed

                            Selecta Biosciences

                            U.S.A arrow
                            2024 ACI Convention
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Pegadricase

                            Therapeutic Area : Musculoskeletal

                            Study Phase : Phase II

                            Sponsor : Swedish Orphan Biovitrum AB

                            Deal Size : Undisclosed

                            Deal Type : Licensing Agreement

                            DEALS_DEV arrow-down

                            Sobi and Selecta Announce Strategic Licensing Agreement for SEL-212, a Phase 3-ready Novel Treatment for Chron...

                            Details : This strategic licensing agreement is for SEL-212, a combination of Selecta's tolerogenic ImmTOR immune tolerance platform and a therapeutic uricase enzyme (pegadricase) for the treatment of chronic refractory gout.

                            Brand Name : Undisclosed

                            Molecule Type : Large molecule

                            Upfront Cash : Undisclosed

                            June 11, 2020

                            Lead Product(s) : Pegadricase

                            Therapeutic Area : Musculoskeletal

                            Highest Development Status : Phase II

                            Sponsor : Swedish Orphan Biovitrum AB

                            Deal Size : Undisclosed

                            Deal Type : Licensing Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth